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Oral peptide and protein delivery: Intestinal obstacles to delivery and commercial 
prospects 
Abstract 
Introduction: Pharmaceutical research and development is increasingly focussed on 
biologicals including peptide and protein drugs.  Despite their growing importance and 
almost 100 years of research the vast majority are still only available by injection.  Oral 
bioavailabilities of peptide and protein drugs are very low mainly because of the stability and 
permeability barriers of the gastrointestinal tract.   
Areas Covered: Data from studies of peptide/protein drug oral bioavailability, stability and 
permeability in the stomach, small intestine and large intestine has been compiled to make 
comparisons between the various regions of the gastrointestinal tract and peptides and 
proteins with differing characteristics.  Assessment of the oral formulation strategies which 
have progressed farthest in clinical trials has been conducted to identify which have the best 
potential for future success. 
Expert Opinion: The oral delivery of peptides and small proteins is becoming increasingly 
likely by utilising formulations which combat the stability challenges of the gastrointestinal 
tract and disrupt the intestinal cell membranes to enable absorption.  However oral 
bioavailabilities remain low and therefore high, potentially toxic and expensive doses of the 
peptide/protein drugs are needed to elicit a therapeutic effect.  There is very little research 
into larger proteins making their oral delivery unlikely in the near future. 
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1.0 Introduction 
Numerous peptide and protein drugs are available for a wide variety of therapeutic 
applications   Productivity in research and development by large pharmaceutical companies 
has declined and with it focus has shifted from small molecule therapeutics to biologicals 
such as peptides and proteins 1.  Patent applications by leading pharmaceutical companies for 
biologicals now exceeds that of small molecules and this gap is widening.  Reflecting this the 
top selling pharmaceutical drugs of 2012 were protein drugs, more specifically antibodies; 
adalimumab (Humira®, Abbvie) and infliximab (Remicade®, Johnson & Johnson, Merck & 
Co.)2.  Of the top ten selling drugs seven were protein drugs. This shift away from smaller 
molecules towards larger biologicals presents new challenges to formulators. 
Peptide therapeutics is a dynamic and growing part of the pharmaceutical industry with more 
than 100 peptide and protein therapeutics currently marketed worldwide, approximately 270 
peptides in clinical testing and over 400 in pre-clinical development 3, 4.  Biotechnological 
advances have enabled their production on a commercial scale and the therapeutic peptide 
market is predicted to grow from €5.3 billion in 2003 to €11.5 billion in 2013 3.  However 
this represents less than 2% of the global pharmaceutical market, estimated to reach €770 
billion in 2013. 
Despite the importance and growth of the peptide and protein therapeutic area, very few are 
available orally.  The vast majority are only available by injection despite oral preparations 
being the most desirous dosage form from both the patient and pharmaceutical 
manufacturer’s view.  The gastrointestinal (GI) tract contains numerous obstacles to oral drug 
delivery and high inter and intra subject variability makes oral delivery of even small 
molecules challenging 5.  These obstacles are multiplied for peptide and protein therapeutics 
as they are natural substrates for gastrointestinal degradation. 
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Among the few orally available peptide and protein drugs are pancreatin, vancomycin, 
octreotide, desmopressin and linaclotide.  Oral delivery for these drugs is possible due to their 
unique characteristics or their delivery requirements.  Pancreatin, vancomycin and linaclotide 
are orally delivered as their site of therapeutic action is in the GI tract.  Pancreatin is 
delivered to the small intestine to replace a lack of pancreatic enzymes and vancomycin is 
delivered to the colon to treat Clostridium difficile infection.  Pancreatin is generally 
enterically coated to protect the enzymes from denaturation in the stomach.  The 
glycosylated, tricyclic structure of vancomycin may offer protection from enzymatic 
digestion.  Linaclotide is used to treat irritable bowel syndrome and binds a receptor locally 
in the intestinal epithelium6.  Its spiral structure fixed by three disulphide bonds may aid its 
intestinal stability. 
Desmopressin and cyclosporine A are absorbed from the GI tract into the systemic 
circulation.  Cyclosporine A possess’ some unique characteristics amongst peptides that make 
it suitable for oral delivery.  It has an oral bioavailability of approximately 30%, much greater 
than for most peptide and protein drugs.  Unlike most peptides and proteins it is highly 
lipophilic (logP 3) which may enable its partition across the lipid membranes of intestinal 
cells.  Its bioavailability is actually limited by this high lipid solubility as its aqueous 
solubility is low.  Formulations of cyclosporine A are pre-concentrates of oil and surfactant 
that upon contact with GI fluid form emulsions or microemulsions.  Cyclosporine A also has 
a cyclic structure which may provide protection from digestive enzymes. 
Desmopressin does not possess the lipophilicity of cyclosporine A, logP -1.95 7, and is only 
part cyclised so may have less enzymatic protection, yet it is orally delivered.  Its oral 
bioavailability is less than 1% but as only a very low dose is required to elicit its therapeutic 
effect only a very low oral bioavailability is required.  Its wide therapeutic window also 
minimises any problems encountered by variations in oral absorption. 
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Currently the vast majority of peptide and protein drugs are not delivered orally due to their 
low oral bioavailability.  Table 1 lists the bioavailabilities of peptide and protein drugs when 
administered orally or directly to various intestinal segments of humans and animals.  With 
the exception of cyclosporine A, due to the reasons discussed above, all of the peptides and 
proteins listed have bioavailabilities of less than 5% in conscious animals, relative to 
intravenous or subcutaneous delivery, regardless of their size and location of administration.  
The low bioavailabilities displayed in table 1 reveal that even if peptide/protein delivery is 
targeted to a specific part of the GI tract it will still experience huge obstacles to its stability 
and absorption.  Bioavailabilities were slightly higher when drugs were administered to the 
jejunum compared to the other segments, however the results were gathered from many 
different studies which may have used different parameters making comparisons difficult.  
Most of the studies weren’t conducted in humans so may not be representative of the oral fate 
of peptide and protein drugs in humans.   
This review aims to more closely identify the barriers to oral peptide/protein delivery which 
must be overcome by formulators.  This may enable reduction of the costs and complexity of 
the proposed delivery strategies.  Identification of trends in structure and size with 
bioavailability may allow research to focus on those drugs and oral delivery strategies with 
the best potential for success.  The formulations which are showing the most potential in 
human clinical trials have also been assessed to determine which strategies are most likely to 
make universal oral peptide and protein drug delivery possible. 
2.0 Stability 
2.1 Gastric instability 
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The first major barrier faced by an orally delivered peptide or protein drug is the stomach.  
The stability of peptide and protein drugs has been assessed using simulated gastric fluid 
either with or without pepsin and in animal or human gastric fluids as shown in table 2. 
The stomach contains two major threats to stability; acid and pepsin.  Gastric pH may alter 
the ionisation of amino acids affecting the bonds that hold together the secondary and tertiary 
structure of larger peptides and proteins causing a loss of specific structure and function.  
Pepsin cleaves peptide bonds within a peptide chain (endopeptidase) between hydrophobic, 
preferably aromatic amino acids. 
Table 2 indicates gastric stability of peptides and proteins is at least partly dependent on their 
size.  The smaller peptides have high stability in gastric fluids and mucosa.  This may be due 
to their lack of higher structure which could be disrupted by acid and lack of specific pepsin 
cleavage motifs.  The disulphide bridges of oxytocin, vasopressin and linaclotide may also 
provide protection from pepisn.  However mid-sized peptides such as vasoactive intestinal 
peptide were degraded by pepsin but their relatively simple structure remained stable in acid 
alone 8.  The larger peptides and proteins appear to be susceptible to gastric denaturation and 
would need enteric protection for oral delivery.  However for smaller peptides not susceptible 
to acid denaturation and pepsin digestion gastric protection may not be necessary. 
2.2 Small intestinal instability 
The small intestine is the major site of peptide and protein digestion and therefore represents 
a barrier to oral peptide and protein drug delivery.  The small intestine contains luminally 
secreted proteases and membrane bound peptidases.  Peptides and proteins with cysteine 
residues may also be degraded by thiol-disulfide exchange reactions by reduced glutathione.  
Glutathione is part of the antioxidant defence system of the GI tract 
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The peptides tested in small intestinal fluids displayed a similar size dependent stability as 
that seen in the gastric fluids, table 3.  Stability decreased with increasing size, possibly due 
to the presence of more enzyme cleavage sites.  However unlike the gastric fluids only the 
very smallest peptides were completely stable in the small intestinal fluids.  This may be due 
to the presence of more than one protease in the small intestinal fluids.  The proteins tested in 
the simulated small intestinal fluids actually showed greater stability than the large peptides.  
This may be because proteins do not have as easily accessible peptide bonds as their peptide 
chains are involved in complex secondary and tertiary structures.  However, if orally 
delivered these structures may be unfolded in the stomach and so would be vulnerable to 
enzymatic digestion.  These results show that formulation protection from small intestinal 
proteases is essential for successful oral delivery of all but the smallest peptides. 
Degradation of peptides was generally reduced in the intestinal mucosal homogenates 9 and 
proteolytic activity was found to be lower here compared to the lumen 10.  Formulations 
which target peptide/protein drug release upon attachment to the intestinal mucosa may 
increase the likelihood of successful oral delivery. 
Different regions of the intestinal tract have been shown to have differing proteolytic 
activities.  Jejunal extracts from rats and brushtail possums were found to have greater 
proteolytic activity than those from the ileum 10, 11.  LHRH was most degraded in brushtail 
possum jejunal extracts than in those from the ileum or duodenum 12, 13 and linaclotide 
showed similar stability in rat intestinal fluids 6.  These results suggest formulations targeted 
to release their peptide/protein drug in the distal small intestine may have an increased chance 
of systemic absorption. 
2.3 Large intestinal instability 
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Large intestinal degradation of peptides and proteins can result from their fermentation by 
colonic microbes or digestion by proteases secreted by these microbes.  Proteolytic activity in 
the large intestinal fluids and mucosa has been found to be lower than in the small intestine of 
brushtail possums 10 and rats 11.  Degradation of LHRH 12, 13, glatiramer acetate 14 and 
desmopressin  15 was lower in colonic fluids and mucosa compared to small intestinal fluids 
and mucosa.  These results indicate the large intestine may be a more attractive target for oral 
peptide and protein drug delivery than the small intestine. 
Table 4 shows despite reduced proteolytic activity degradation of peptides and proteins still 
occurred in large intestinal fluids and mucosa but in general degradation here doesn’t appear 
to be as complete as in the gastric and small intestinal fluids.  There also doesn’t appear to be 
the relationship between size and stability as seen in the other gastrointestinal fluids.  This 
may be because degradation by microbial fermentation is not correlated to size whereas 
enzymatic digestion appears to increase with increasing size.  However there is limited data 
available for peptide/protein drug stability in large intestinal fluids so it is harder to draw 
reliable conclusions. 
3.0 Permeability 
The routes for peptide/protein drug absorption from the intestinal lumen into the systemic 
circulation are between cells, paracellular, through cells, transcellular, by 
endocytosis/pinocytosis or by carrier mediated transport.   
The very low oral bioavailabilities of peptide and protein drugs are not just the result of their 
instability but also poor permeability.  Human colon carcinoma (Caco-2) cells are widely 
used as a model of intestinal epithelium for studying transepithelial drug transport.  In Caco-2 
cell absorption studies there was no uptake of erythropoietin and granulocyte colony 
stimulating factor (GCSF) 16 negligible salmon calcitonin transport  17 and even with the very 
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small peptide thyrotropin releasing hormone (TRH) more than 90% of the drug remained on 
the donor side 18.  Absorption by Caco-2 cells may however underestimate in vivo absorption 
as they resemble colonic more than small intestinal tissue and have tighter junctions.  This 
may explain poor correlations seen between the absorption of peptides in Caco-2 cells and rat 
intestinal cells 19.   
Permeability has been found to be size dependent and decreases rapidly when molecular 
weight is greater than 700Da 20-22.  As even the smaller peptides are larger than 700Da their 
intestinal absorption is likely to be very limited. The paracellular route may be more 
compatible with hydrophilic peptides and proteins but is particularly limited by the tight 
junctions between cells and restricted to molecules less than 200Da 20-22.  The paracellular 
spaces also contribute less than 1% of the total mucosal surface 23.   
Most peptide and protein drugs are hydrophilic and therefore not compatible with passive 
transcellular absorption.  The lipophilic nature of cyclosporine A is thought to account for its 
higher oral bioavailability.  However poor correlations between the lipophilicity of peptides 
and their uptake across the Caco-2 in vitro intestinal cell model 24 and rat ileum 25 have been 
observed.  Instead both studies found the more hydrogen bonds a peptide could form with 
water the less permeable it was, possibly due to the greater amount of energy required to 
break these bonds before absorption.  Methylation of model peptides increased Caco-2 cell 
permeability of model peptides by reducing hydrogen bonding potential 24.   Conformational 
flexibility and molecular radii have therefore been shown to be at least as crucial as 
lipophilicity for absorption. 
These studies show that the best candidates for oral delivery are small peptides with high 
flexibility and low H-bonding potential.  Modifying proteins and peptides by reducing H-
bonding potential may be a good option for increasing oral peptide/protein drug 
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bioavailability but any modifications should not impair the therapeutic efficacy of the drug.  
Many potential delivery strategies have employed components to open the paracellular 
channels or disrupt the cell membranes to increase permeation.  However these risk the 
absorption of not just the drug but potentially toxic entities.   
The most permeable segment of the gastrointestinal tract is the small intestine due to its large 
absorptive surface area and leakier paracellular channels than those found in the large 
intestine or stomach.  Absorption of the following peptides was greater from the small 
intestine than the stomach or large intestine when administered to GI tract segments in rats 
and dogs: vasopressin 26, calcitonin 11, 27-29, azetirelin 30 and desmopressin in humans 31.  
These results indicate that for successful oral delivery peptide and protein drugs should be 
targeted to the small intestine for absorption. 
Studies which compared the absorption of peptide and protein drugs from small intestinal 
segments in rats, beagle dogs and rabbits found that calcitonin 11, 27, 28, insulin 32, oxytocin, 
carbetocin 33, desmopressin, vasopressin 33, 34, azetirelin  30 and leuprolide 35 showed greater 
absorption from the distal than proximal small intestine.  This may be due to lower 
proteolytic activity in the ileum than the jejunum.  The M cells of gut associated lymphoid 
tissue are known to sample macromolecules from the ileum and may be able to increase 
peptide/protein absorption from this segment.  In human studies, however, desmopressin 31 
and octreotide 36 absorption was greater from the proximal small intestine than the ileum.  
This disparity with animal absorption studies could be due to their higher percentage of M 
cells in Peyer’s patches, 10-50%, in rodents, and 46% in rabbits 37 compared to 5% in 
humans.   
4.0 Oral delivery strategies 
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To overcome the stability and permeability barriers to oral peptide and protein delivery many 
different strategies have been attempted and are listed in figure 1.  They have been reviewed 
extensively elsewhere 38-41.  Strategies to overcome the gastric barrier include enteric carriers 
and coatings to protect the peptide/protein drug or delivery with excipients to raise the gastric 
pH.  To overcome the enzymatic obstacles of the small intestine formulations with protease 
inhibitors and excipients which lower the pH have been developed.  Colonic targeted dosage 
forms have also been formulated to circumvent the more degradative conditions of the 
stomach and small intestine.  To increase intestinal permeation excipients which can open 
paracellular channels, disrupt the intestinal membrane and increase mucoadhesion have been 
utilised.  The peptides and proteins to be delivered have also been modified by lipidisation or 
conjugation to targeting ligands to increase absorption.  Incorporation into polymeric and 
lipid nano/microparticles, micelles, liposomes and emulsions has also been investigated.  
These can provide protection to the encapsulated peptides and proteins and increase 
permeation.  While these strategies have academic interest very few have reached human 
clinical trials. 
The vast majority of oral delivery research has been conducted with calcitonin and insulin, 
possibly due to the frequency of their administration and clinical importance.  Some research 
has also focused on improving the oral delivery of cyclosporine A, desmopressin and 
pancreatin.  There has also been research conducted with the peptide hormones leuprolide, 
oxytocin and octreotide possibly due to their smaller size making them more compatible for 
oral delivery.  There has been very little investigation into the oral delivery of larger proteins.  
This could be because of the inherent difficulties of maintaining their complex structure 
during GI transit and the greater difficulty of absorption of such large molecules.  Recently 
the oral delivery of glucagon like peptide-1 (GLP-1) and its analogues exenatide and 
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liraglutide has been explored possibly due to their importance in the treatment of type 2 
diabetes. 
4.1 Commercial oral delivery strategies 
In addition to academic research and development many biotechnology companies have also 
been pursuing oral peptide and protein formulations.  This has met with mixed success.  
Unfortunately many strategies which demonstrated promising results in preclinical or early 
stage clinical trials have been discontinued meaning their full potential has not been fully 
realised. 
4.1.1  Discontinued/inactive oral delivery strategies 
AutoImmune with Eli Lilly and Provalis with Cortecs Ltd developed oral insulin 
formulations which showed efficacy in phase II clinical trials but they have since been 
suspended.  Oral insulin delivery strategies developed by Endorex, based on liposomes, by 
Apollo Lifesciences, based on vitamin B12 coated nanoparticles, and by Bow 
pharmaceuticals, based on encapsulation in a dextran matrix, have also been suspended.  
Diasome developed a nanosized oral insulin that was stable at low pH and in the bloodstream.  
This was tested in phase II and III clinical trials with type II diabetics in 2009 but there have 
been no further trials or information regarding this product.   
Oral formulations of insulin, developed by Diabetology, and calcitonin, by Bone Limited, 
demonstrated efficacy in Phase I and IIa clinical trials using Axcess™ delivery technology.  
This delivery technology involves encapsulation in enteric coated capsules with an absorption 
enhancer and bile acids.  These trials were conducted in 2004 and 2005, there have been no 
further trials but Diabetology recently announced a partnership with USV Limited to develop 
oral insulin for the Indian market.   
12	  
	  
Unigene completed a phase II clinical trial with their oral parathyroid hormone formulation in 
November 2011 successfully meeting endpoints.  The formulation included digestion 
inhibitors and absorption enhancers and increased oral bioavailability from <1% to 20%.  
However this project has now been suspended. 
4.1.2  Current oral delivery strategies in clinical trials 
Despite the suspension of many projects some have completed successful clinical trials and 
are pursuing filings in the near future.  These active programs are outlined in table 5. 
Emisphere’s Eligen® technology utilises delivery agents, which interact non-covalently with 
peptide and protein drugs exposing their hydrophobic side chains, increasing their 
lipophilicity and absorption.  This strategy was one of the most promising for peptide/protein 
delivery increasing the oral bioavailabilities of parathyroid hormone42 , human growth 
hormone 43, salmon calcitonin44 and interferon-α43 in rats and primates.  However, a three 
year phase III clinical trial with salmon calcitonin, which ended in 2011, failed to meet 
primary and secondary endpoints in treating postmenopausal osteoporosis and its planned 
2012 submission has been abandoned.  Its oral programs for parathyroid hormone, human 
growth hormone and insulin for type I diabetes have all been terminated.  Its remaining oral 
delivery program is with GLP-1 analogs and insulin for type 2 diabetes which entered phase I 
clinical trials in 2010. 
Biocon have continued the development of an oral insulin formulation, IN-105, initiated 
originally by the Nobex Corporation.  Phase III clinical trials did not meet desired 
expectations, but this was not thought to be due to a lack of efficacy necessarily but due to 
behavioural modifications of those taking the placebo.  The project is still active though and a 
partnership with Bristol-Myers-Squibb for further development appears likely.   
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The other oral peptide/protein delivery system that has completed phase III clinical trials is 
Tarsa Therapeutic’s OSTORA™, salmon calcitonin tablet.  It successfully met all clinical 
endpoints and represents the most promising oral peptide strategy for future availability 45.  
However an FDA Advisory Committee decided in 2013 that salmon calcitonin should no 
longer be broadly marketed as the risk of it causing cancer outweighs its benefits.  This 
unfortunately may end the progress of this oral peptide which had progressed much farther 
than many others. 
Chiasma’s oral octreotide is currently undergoing phase III clinical trials and they are hopeful 
of filing a new drug application (NDA) in the near future.  A new partnership with Roche was 
announced in February 2013 to develop and commercialise Octreolin™.  Amarillo 
Bioscience’s oral formulation of interferon α and Oramed’s oral insulin and exenatide have 
entered or completed phase II clinical trials and it remains to be seen if they can progress to 
further clinical trials.   
The programs all involve peptides/proteins of less than 6kDa, except for interferon α which is 
targeted to throat receptors and so doesn’t have to overcome the stability and permeability 
issues of oral systemic delivery.  The oral delivery of larger proteins to the systemic 
circulation does not look like becoming a reality soon.  However the success of Tarsa 
Therapeutic’s phase III clinical trial with calcitonin suggests it may not be long before 
relatively large, hydrophilic peptides can be administered orally.   
The formulations developed by Tarsa, Chiasma and Oramed all comprise protective and 
permeation enhancing elements.  The dosage forms developed by Tarsa and Oramed are 
enteric coated, have protease inhibitors and permeation enhancers which can disrupt the 
intestinal membrane.  Chiasma’s formulation involves delivery in a protective hydrophobic 
medium with permeation enhancers.  These strategies have the best potential for future 
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success and indicate that formulations need to provide protection from acid and enzymes and 
permeation enhancement. 
Emerging oral peptide/protein drug delivery strategies in preclinical or entering clinical trials 
seem mainly to be based on modified nanoparticles.  Access Pharmaceuticals have 
formulated peptide and protein drugs in nanoparticles coupled to cobalamin, a vitamin B12 
analog.  NOD Pharmaceuticals are currently conducting phase I clinical and preclinical trials 
with oral insulin and exenatide mucoadhesive nanoparticles.  NanoMega Corp have 
encapsulated insulin in chitosan shelled gamma γ-PGA nanoparticles and Oshadi drug 
administration have blended insulin with inert silica nanoparticles, a polysaccharide, 
suspended them in oil and loaded into enteric capsules.   
5.0 Conclusion 
Oral bioavailabilities of peptide and protein drugs are generally very low, table 1.  Despite 
oral delivery being the most desirous drug delivery route very few peptide and protein drugs 
are orally available.  The main obstacles to oral peptide and protein delivery, stability and 
permeability, vary amongst peptides and proteins and differ in the various segments of the GI 
tract.  Analysis of these can identify the best candidates for oral delivery and the segments of 
the GI tract to be targeted for drug release and absorption. 
Reviewing the studies of peptide and protein stability in gastric and small intestinal fluids 
revealed that small peptides were most stable and some of these may not need any gastric 
protection.  Contrary to this trend larger proteins appeared more stable in simulated small 
intestinal fluids than small proteins and large peptides. They were however susceptible to 
gastric denaturation so would require enteric protection. There was no apparent correlation 
between stability in large intestinal fluids and peptide/protein size or structure.  The majority 
of peptides and proteins tested were vulnerable to digestion by gastric, small intestinal and 
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large intestinal fluids and will need protection to enable their oral delivery.  A review of 
peptide/protein intestinal permeability revealed permeability reduced with increasing size, 
hydrophilicity and H bonding potential.   
The small intestine presented the greatest enzymatic barrier to oral peptide and protein 
delivery.  Of the small intestinal segments the jejunum was most proteolytic.  While the large 
intestine and stomach may be more favourable for oral delivery for some proteins and 
peptides as they have a lower stability barrier they are not as permeable as the small intestine.  
The proximal small intestine appeared the most favourable segment for uptake in humans, 
possibly due to wider paracellular channels here. 
While many drug delivery strategies have been developed very few have reached clinical 
trials.  Those that have and that have the greatest potential for becoming commercially 
available are those for peptides with a wide therapeutic window and which use multiple 
approaches for protection and permeation.  The number of discontinued trials indicates that 
oral systemic delivery is a huge challenge, particularly for proteins, and while oral delivery 
may soon be a reality for peptides for proteins this goal remains currently out of reach. 
6.0 Expert Opinion 
The goal of universal peptide and protein drug delivery has been pursued since the discovery 
of insulin 90 years ago but as yet very few are orally available.  With the pharmaceutical 
industry increasingly focussed on biological drugs the drive for oral peptide and protein drugs 
has never been greater.  The achievement of oral delivery for all peptide and protein drugs 
would elicit huge improvements in the quality of life of patients who rely on chronic, 
injectable doses of therapeutic peptides and proteins.  It would also mean cost savings in 
terms of production and administration for the non-sterile, oral formulations.  
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To achieve universal oral peptide and protein drug delivery greater understanding of their 
gastrointestinal stability and permeability and what affects these is needed.  This will enable 
better selection of drug candidates, targeting of optimal gastrointestinal regions for uptake 
and improved formulation selection.  While peptide and protein drugs have been tested in 
simulated and animal gastrointestinal fluids/tissues there has been limited testing in human 
fluids/tissues and this will be needed to increase the chance of success in humans. There have 
been very few oral formulations which have been clinically trialled compared to all the 
delivery strategies which have been developed and tested in vitro and in animals.  More trials 
in humans are needed to increase the likelihood of oral delivery success. 
The strategies which have proved most successful in clinical trials are combinations of many 
strategies.  They combine encapsulation of the protein/peptide drug in multiparticulates, 
capsules or tablets with protease inhibitors and permeability enhancers, especially medium 
chain fatty acids.  They may also be enteric coated or conjugated to targeting ligands.   
As many of these delivery strategies may disrupt normal digestive processes and compromise 
the barrier function of the GI tract to incoming toxins implications of their long term use 
should be considered.  Oral bioavailabilities should be reproducible and reliable to achieve a 
regulatory filing but incompatibility of hydrophilic peptide and protein drugs with 
hydrophobic delivery carriers can produce uncontrolled drug release46.  Reproducible 
bioavailabilities may also be compromised by intra or inter subject variation in the GI 
environment as peptide and protein drug absorption is so highly dependent on its 
characteristics.  Those drugs with a wide therapeutic window, such as the currently orally 
available desmopressin, may be more compatible for oral delivery due to this variability.  
Octreotide and calcitonin have large therapeutic windows and this may partly explain the 
progression of their oral formulations to phase III clinical trials. 
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Despite the failures encountered during clinical trials and the suspension of many projects 
oral peptide/protein drug formulations are likelier than they ever have been.  The success of 
Tarsa Therapeutics’ oral salmon calcitonin in clinical trials increases the probability that 
other peptide and protein drugs will soon be orally available. 
Oral bioavailabilities are still much lower than those of injected doses and therefore much 
higher doses must be administered orally to have the same effect.  For more expensive 
peptide and protein drugs this could preclude their oral delivery.  The toxicity implications of 
administering relatively large doses of peptide and protein drugs orally must also be 
considered. 
Challenges for the future may be the scaling up for manufacture of the more complex 
formulations.  Research and clinical trials have mainly focused on the delivery of oral 
peptides rather than proteins.  Their larger size seems to multiply the challenges of oral 
delivery and this may have deterred development.  While oral peptide delivery may soon be 
more widely available oral protein delivery to the systemic circulation may take longer and 
require strategies more specifically designed for them. 
Article Highlights 
• Peptide and protein drugs represent a large and growing share of the pharmaceutical 
market yet few are orally available. 
• Poor gastrointestinal stability and permeability are factors in the low oral 
bioavailability of peptide and protein drugs but there are few human studies 
investigating their gastrointestinal stability and permeability. 
• Studies in simulated, animal and some human gastrointestinal fluids and tissues reveal 
that the smallest peptides are most suited to oral delivery and that some of these may 
not require enteric protection. 
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• The small intestine is the most degradative environment for the widest range of 
peptides and proteins but it is more permeable than the stomach or large intestine. 
• Numerous oral peptide and protein drug delivery strategies have been investigated but 
few have been clinically trialled.  The most successful trials utilised multiple 
approaches for enhanced stabilisation and permeation and involved peptides with 
wide therapeutic windows. 
• Very few clinical trials have involved delivery of large proteins therefore it appears 
unlikely these will be available orally soon. 
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 Table 1  Bioavailabilities of peptide/protein drugs when administered orally or to intestinal segments in humans/animals 
Peptide/protein 
(amino acids, size) 
Site of administration-bioavailability relative to intravenous/subcutaneous dose (%) 
Oral Stomach Duodenum Jejunum Ileum Colon 
TRH–rat  (3, 0.4kDa) 1.6%47      
Vancomycin-rat (7, 1.4kDa) 1.7%48      
Octreotide-human (8,1kDa) 1.26%49 0.2% sc36 0.1% sc36 0.2% sc36 0.06% sc36  
Octreotide-rat (8, 1kDa) 4.3%49   0.3%-3.1%49-
51  
  
Octreotide-pig    1.7%51   
Leuprolide-rat (9, 1.2kDa) 0.02-0.3% 
1.2% sc52-54 
 0.08%52 1.3*% 35 0.6-5.6*% 35 0.4-9.6*%35 
Buserelin-rat (9,1.3kDa)   0.1-0.8%55, 56    
Vasopressin analogs-rat (9/10, 1.1kDa) <0.1%57   0.9%50   
Desmopressin-human (10, 1.1kDa)  0.2%31 0.09-0.2%31, 58 0.2%31 0.03%31 0.04%31 
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Cyclosporine A-human (11, 1.2kDa) 20-50%59      
Linaclotide- rat (14, 1.5kDa) 0.1%6      
Calcitonin-rat (32, 3.4kDa) 0-0.2%27, 60-
62 
 0.02-0.15%11, 27, 63 0.2-3.3%11, 64 0.06%27 0.02-0.9%11, 27, 62, 65 
Calcitonin-human  0.8%66     0.22%67 
Calcitonin-dog    0.04%28  0.06%28 0.02%28 
Exenatide-rat (39, 4.2kDa) 0%68  0.005%69    
Insulin-rat (51, 5.8kDa) 0.7%, 
<1%61, 70 
  0.021%71 0.25%72 0.091%71, 0.2%72 
Parathyroid hormone-rat/monkey  
(84, 9.4kDa) 
0% 42, 73    0%73  
Erythropoietin-rat (106, 18kDa)    0.6%74   
Interferon α-rat/rabbit (165, 19kDa)  0%75 <1% 75  
GCSF-rat (175, 19kDa)   0%76    
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Human Growth Hormone rat (191, 22kDa)  0.8%77 1.0%77  0.7%77 0.2%77 
* In anesthetized rats.  Thyrotropin releasing hormone (TRH), granulocyte colony stimulating factor (GCSF).   
Bioavailabilities are relative to an intravenous dose, unless specified as relative to a subcutaneous dose (sc).  
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Table 2 Peptide/protein recovery after incubation in simulated gastric fluid (SGF), human/animal gastric fluid and mucosa 
Peptide/protein 
(amino acids, size) 
Proportion intact/active after incubation in simulated/human/animal gastric media 
SGF no pepsin SGF pepsin Gastric fluid Gastric mucosa 
TRH (3, 0.4kDa)  100% 2hours47, 78 100%-2 hours rat47, 78  
Oxytocin (9, 1kDa)   100% human9 100% human9 
Vasopressin  (9/10, 1.1kDa)   100% human9 100% human9 
Leuprolide (10, 1.2kDa)  60%, 6 hours79   
Linaclotide (14, 1.5kDa) 100% 3hrs6 100% 3 hours6   
Vasoactive intestinal peptide (28, 3.3kDa) 100%8 0% immediate8   
Teriparatide (34, 4.1kDa)  0% 5 mins80   
Insulin (51, 5.8kDa)  3%-10% 2 hours32, 81 
0% 3 minutes82 
0% 3 mins- pig82  
Lysozyme (128, 14.3kDa) 0% 30 mins83    
β-lactoglobulin A/B (162, 18.4kDa) 17.2-34.3% 60 mins83 0% 2 mins83   
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Ovomucoid (28kDa)  0% immediate83   
Parathyroid hormone (84, 9.4kDa)  0% 5 min73   
Trypsin  
(223, 23kDa) 
 8% 30 mins84   
Lipase (460, 45-50kDa)  0% 30 mins, 3% 10 mins84   
Amylase (496, 51-54kDa) 0% 2 hours85 0%, 30 mins, 2% 5 mins84   
BSA (583, 66.5kDa)  0% immediate83   
Chicken egg yolk immunoglobulin (150kDa)  0% 1 hour86   
Luteinising hormone releasing hormone (LHRH) 
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Table 3  Peptide/protein recovery and half lives (HL) in simulated intestinal fluid (SIF), human/animal small intestinal fluid and mucosa  
Peptide/protein 
(amino acids, size) 
Proportion remaining and half lives after incubation in human/animal small intestinal fluid/mucosa 
SIF Small intestinal fluid Small intestinal mucosa 
TRH (3, 0.4kDa)  100%, 3hrs78 Rat proximal-100%47 Rat-100%47 Rabbit jejunal-94% 65 min87 
Hexarelin (6, 0.9kDa)  Rat jejunal/ileal- 80%/60% 1hr88  
Octreotide (8, 1kDa)   Rat-100%49 
Oxytocin analogs (9, 1kDa)  Human ileal-0% 60mins9 Human jejunal/ileal 100%9 
Vasopressin analogs (9/10, 
1.1kDa) 
 Human ileal 0% 30 mins9 
Rat-0.2-58.3% 30 mins57 
Pig pancreatic juice 0% 5 mins89 
Human jejunal-30% 3hrs, 
ileal 100% 3 hrs9 
Rabbit 2 mins and 40 mins half life89 
Desmopressin (10, 1.1kDa)  Pig pancreatic juice 100% 60 mins89 
Human ileal 50% 35 mins9 
Rabbit 9 mins and 161 mins half life 89,  
Human jejunal-30% 3hrs9 
Gonadotrophin releasing 
hormone analogs (9/10, 1.2-
0%, immediate79 Brushtail possum jejunal- 22 min HL10 Rabbit-1.1% 1hr90 
Rat-24.8% 5 hr90, 90 min HL91 
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1.3kDa) 
Linaclotide (14, 1.5kDa)  Rat duodenum 0.4 min HL, jejunum 0.4 min 
HL, ileum 36 min HL6 
 
Vasoactive intestinal peptide 
(28, 3.3kDa) 
0% immediate8   
Calcitonin (32, 3.4kDa) 0%, 1hr92 Rabbit- 20 min HL93 
Rat-jejunal 0% 5min, 0.4 min HL60 
Rabbit brush border enzymes- 239 min HL93 
Rat jejunal- 0% 25 min11, 4.1-10.6 min HL60, 
94, Rat ileal 5.59 min half life11 
Teriparatide (34, 4.1kDa)   Rat- 50% 3 hr80 
GLP-1 analogs (39, 4.2kDa)  Rat proximal-0.51-1.76 min HL68, 95 
Rat jejunal 0.57 min HL96 
Rat proximal- 0.79 min HL95 
Insulin (51, 5.8kDa) 10% 2hr81 Pig-0% 3 min82  
Lysozyme (128, 14.3kDa) 22.8%, 1 hr83   
Ovomucoid (28kDa) 23.4%, 1 hr83   
BSA (583, 66.5kDa) 17.7%, 1 hr83   
